Analysts See $-0.26 EPS for NantKwest, Inc. (NK)

NantKwest, Inc. (NASDAQ:NK) Logo

Analysts expect NantKwest, Inc. (NASDAQ:NK) to report $-0.26 EPS on November, 6.They anticipate $0.04 EPS change or 13.33 % from last quarter’s $-0.3 EPS. After having $-0.17 EPS previously, NantKwest, Inc.’s analysts see 52.94 % EPS growth. The stock increased 7.21% or $0.08 during the last trading session, reaching $1.19. About 145,082 shares traded. NantKwest, Inc. (NASDAQ:NK) has declined 60.12% since October 4, 2018 and is downtrending. It has underperformed by 60.12% the S&P500.

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company has market cap of $116.99 million. The firm develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It currently has negative earnings. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors.

More notable recent NantKwest, Inc. (NASDAQ:NK) news were published by: which released: “Are Natural Killer Cells the Next Big Thing in Immunotherapy? – Motley Fool” on July 08, 2019, also with their article: “Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting – Benzinga” published on October 02, 2019, published: “CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunotherapy Congress – GlobeNewswire” on September 24, 2019. More interesting news about NantKwest, Inc. (NASDAQ:NK) were released by: and their article: “NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics – Yahoo Finance” published on June 04, 2019 as well as‘s news article titled: “Fate Therapeutics to Present at the Jefferies 2019 Healthcare Conference – GlobeNewswire” with publication date: May 30, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.